Overview

A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC

Status:
RECRUITING

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

This study aims to explore the efficacy and safety of the combination therapy of utidelone and capecitabine in the treatment of brain metastases from triple-negative advanced breast cancer, and to search for systemic treatment for brain metastases from triple-negative advanced breast cancer cases.

Phase:

PHASE2

Details

Lead Sponsor:

Henan Cancer Hospital

Treatments:

Capecitabine